GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC

GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Acuta Capital Partners

Cormorant Asset Management

RA Capital Management

RTW Investments

Logos Capital

Biotechnology Value Fund

Boxer Capital

BVF Partners

Surveyor Capital

Venrock Healthcare Capital Partners

Verition Fund Management

GH Research plc

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

https://lnkd.in/eEJUSZpQ

COM:GHRES